Suven Life Sciences Receives Two Product Patents in India, USA | CORPORATE ETHOS

Suven Life Sciences Receives Two Product Patents in India, USA

By: | December 11, 2017
suven

Dec 11: Hyderabad-based bio-pharma major Suven Life Sciences Ltd on Monday announced the grant of one product patent from India (289123) and one product patent from USA (9790211) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2033 respectively.

The granted claims of the patents include the class of selective Alpha4 Beta2 and 5-HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia respectively

Commenting on the development, Venkat Jasti, CEO of Suven, said, “we are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.